Alto Neuroscience, a clinical-stage biopharmaceutical company focused on personalized psychiatry via its proprietary Precision Psychiatry Platform, reported in its latest quarterly filing ongoing clinical development of seven product candidates targeting major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s-related depression. It remains pre-revenue but strengthened its liquidity position through two recent private placement financings totaling nearly $165 million net proceeds. The company plans to advance multiple Phase 2b and Phase 3 trials while preparing for potential regulatory approvals and commercialization investments. Key risks include the inherent uncertainties of clinical outcomes, required companion diagnostic development, regulatory approvals, and building commercialization capabilities.